– Merging AI robot control and wireless networks… Presenting an impactful vision enabling short- and long-term revenue growth by evolving beyond a simple network equipment supplier into an integrated robot automation control design company

– A strategic move to restore shareholder trust, preempt future industrial markets, and compete through technology convergence

ANYANG, South Korea, Feb. 23, 2026 /PRNewswire/ — DAVOLINK, a network security and solutions specialist, is strategically merging with LoadRunner, a smart factory solutions provider. This move signals its transition beyond being a simple security Wi-Fi equipment supplier to becoming an intelligent communications and security integrated platform company.

Following its recent announcement of plans to strengthen financial soundness, expand transparent IR, and implement shareholder-friendly policies, DAVOLINK has positioned the technological merger with LoadRunner—beyond an MOU—as a core pillar for future growth.

DAVOLINK’s intent to embrace LoadRunner extends beyond simple cooperation or a robotics technology partnership.

LoadRunner possesses a platform and automation robot technology featuring large-scale data processing, AI-based analysis, and automated workflow design capabilities, excelling in real-time event processing and building integrated control environments.

It is already expanding business revenue in industrial settings. It is not merely a company presenting a future robotics vision. This distinct advantage is why DAVOLINK chose to pursue integration with LoadRunner at this critical juncture.

By combining DAVOLINK’s expertise in wireless network design, construction, and operation with LoadRunner’s AI analysis engine and robot integration design, DAVOLINK can expand its architecture to simultaneously encompass network infrastructure and data intelligence.

The core of this merger strategy is ‘Intelligent Integrated Control’. While existing network security environments focused on rule-based detection and post-incident response, applying LoadRunner’s AI analysis system and robot technology enables real-time traffic anomaly detection, threat prediction, and automated response processes.

The vast log, traffic, and terminal data collected at the wireless network edge, linked with the central analysis engine, creates a structure where ultra-low-latency analysis and immediate blocking systems operate simultaneously, making it immediately applicable to industrial sites.

DAVOLINK’s wireless network technology already demonstrates competitive strength in enterprise-grade RF design, large-scale endpoint connectivity, edge computing integration, and high-speed traffic management. When combined with LoadRunner’s AI-powered analytics and robotics-integrated control systems, the network itself evolves beyond simple connectivity into an intelligent decision-making system.

This can extend beyond security threat detection to include network optimization, automatic traffic distribution, and predictive failure management.

The convergence of telecommunications infrastructure and AI-based integrated control systems carries significant structural implications for future industrial markets. Industries such as manufacturing, logistics, smart factories, smart cities, defense, and robotics automation generate massive real-time data from IoT sensors, edge devices, and autonomous systems. These sectors require not just connectivity, but intelligent networks capable of analyzing and orchestrating operations in real time.

DAVOLINK and LoadRunner’s integrated strategy reflects this demand. By combining telecommunications, AI, security, robotics, and integrated control design, the partnership targets both near-term revenue opportunities and long-term platform value creation.

This represents more than a technological upgrade. It is a redefinition of the business model.

Rather than remaining focused on hardware sales, DAVOLINK intends to transition toward a platform-as-a-service structure. Following initial network deployment, recurring revenue can be generated through ongoing monitoring services, data analytics subscriptions, and robotics-integrated control system operations.

From an investor perspective, this shift introduces both short-term performance potential and long-term platform scalability as key valuation drivers.

A DAVOLINK executive described the phased integration strategy with LoadRunner as a strategic inflection point that goes beyond technical cooperation to secure global competitiveness for both companies.

Market analysts interpret this as an effort to restore shareholder confidence while presenting a clearly defined growth roadmap. The combination of financial stabilization initiatives and platform expansion strategy reflects a dual-track approach aimed at operational restructuring and future market leadership.

Ultimately, the integration signals DAVOLINK’s evolution from a network infrastructure company into an AI-driven intelligent security and robotics-integrated control platform provider.

As network infrastructure and data intelligence converge, DAVOLINK may position itself as a core infrastructure player within the future robotics and automation ecosystem. Industry experts suggest this strategic move represents a structural transformation designed to secure differentiated global competitiveness through technological convergence.

The company acknowledges investor concerns and has stated its intention to restore trust through transparent execution while simultaneously reshaping its long-term industrial positioning.

By expanding telecommunications capabilities into robotics automation design and integrated control systems, DAVOLINK is presenting what it describes as a realistic, high-impact future technology vision capable of generating both short-term and long-term revenue streams.

With the LoadRunner MOU, DAVOLINK has signaled renewed strategic momentum. Robotics industry analysts view the partnership as symbolically and structurally significant, marking the company’s entry into intelligent robotics-integrated control system design and operations.

CHENGDU, China, Feb. 23, 2026 /PRNewswire/ — The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical stages in the U.S. and China. Concurrently, the company’s “AI + Chemical Induction” platform saw its first U.S. patient dosed for Parkinson’s disease at Weill Cornell Medical Center and its first patient enrolled for Multiple System Atrophy (MSA) at Beijing Tiantan Hospital. These parallel milestones for NouvNeu001 and NouvNeu004 represent the next phase of iRegene’s global strategy, transitioning from early safety data into mid-stage clinical trials designed to rigorously evaluate therapeutic efficacy across international patient cohorts.

First Patient Dosed in U.S. Phase IIa Trial of NouvNeu001 for Parkinson‘s Disease

NouvNeu001 is an investigational off-the-shelf cell therapy derived from induced pluripotent stem cells (iPSCs) and chemically induced into dopaminergic progenitor cells. The therapy was administered via stereotactic neurosurgery into the bilateral putamen at Weill Cornell Medical Center in the first patient of an open-label U.S. Phase II study.

Building on positive Phase I data, the U.S. Food and Drug Administration (FDA) cleared NouvNeu001 for direct Phase II entry in the Q3 2025, following Fast Track Designation (FTD) and Regenerative Medicine Advanced Therapy (RMAT) designation. This progression validates iRegene’s preclinical and clinical package and robust CMC framework, enabling closer FDA collaboration and accelerated pathways.

NouvNeu001 is designed to address the underlying pathology of Parkinson’s disease by replacing lost dopaminergic neurons and modifying disease progression — a “single dose, sustained benefit” approach aimed at addressing critical unmet needs. With the first patient dosed in U.S., parallel Phase II trials continue in both the U.S. and China.

First Patient Enrolled in China for MSA Trial with NouvNeu004

In parallel, iRegene has enrolled the first patient in a randomized controlled clinical trial in China evaluating NouvNeu004, its allogeneic iPSC-derived off-the-shelf cell therapy candidate for Multiple System Atrophy (MSA). Led by Principal Investigator Professor Yilong Wang at Beijing Tiantan Hospital, Capital Medical University, the study marks a significant advancement for MSA – a rapidly progressive neurodegenerative disorder with no approved disease-modifying therapies.

NouvNeu004 employs a dual “neurotrophic support + neural reconstruction” strategy, providing trophic support to affected brain regions while promoting functional neural differentiation to potentially halt or reverse progression. China’s NMPA approved the integrated Phases I–III trial application in October 2025, while the U.S. FDA has granted a special exemption and cleared an international Phase I trial, enabling efficient simultaneous development in both countries.

“Dosing the first U.S. patient for Parkinson’s disease and enrolling the first MSA patient in China are pivotal milestones in our mission to deliver transformative, disease-modifying therapies to patients worldwide,” said Dr. Meng Cai, Chief Medical Officer of iRegene Therapeutics.

“These parallel advances reflect the productivity of our ‘AI + Chemical Induction’ platform, yielding two pioneering ‘off-the-shelf’ cell therapies: NouvNeu001 for Parkinson’s disease and NouvNeu004 for Multiple System Atrophy. Together, they demonstrate our commitment to a robust global development pathway and our continued contribution to the advancement of cell therapy for neurodegenerative diseases.”

The “AI + Chemical Induction” Advantage: From Proof-of-Concept to Industrial Validation

iRegene’s core strategy centers on its proprietary “AI + Chemical Induction” platform, engineered to bring scalability and consistency to cell therapy manufacturing. While traditional differentiation methods frequently rely on complex growth factors and commercial media cocktails – which are often prone to batch-to-batch variability and high costs – iRegene utilizes algorithm-optimized small molecule combinations to direct cellular differentiation toward specific lineages.

This chemical induction approach is designed to reduce batch-to-batch variability and support consistent manufacturing under a stable CMC framework, facilitating true off-the-shelf production at lower costs with reduced supply chain complexity compared to personalized or growth factor-dependent therapies. The platform’s foundational technology has been granted patents across China, Japan, and the U.S.

Building on this foundation, iRegene is developing a pipeline of universal, iPSC-derived cell therapies for currently incurable diseases, led by its flagship program and several novel candidates:

• NouvNeu001 for Parkinson‘s disease – The world’s first clinical-stage, allogeneic iPSC-derived, chemically induced dopaminergic progenitor cell therapy for PD; holds dual FDA FTD (August 2025) and RMAT (December 2025) designations; IND cleared in both China and the U.S.; now in Phase II trials in both China and the U.S.
• NouvNeu003 for early-onset Parkinson‘s disease – The company’s second product candidate. IND approved by China’s NMPA (December 2023); Phase I completed in China.
• NouvNeu004 for Multiple System Atrophy – World’s first “AI + Chemical Induction”-derived cell therapy to enter clinical development for MSA; IND approved by China NMPA covering Phases I–III; U.S. FDA special exemption and international Phase cleared; first patient enrolled in China randomized trial.
• NouvSight001 for Retinal Degenerative Diseases (RDDs) – U.S. FDA Orphan Drug Designation granted (March 2024); advancing as an innovative ophthalmology therapy.

This expanding pipeline underscores the versatility of iRegene’s underlying technology, demonstrating the platform’s capacity to deliver a new generation of scalable cell therapies for complex neurodegenerative disorders. As these candidates move into advanced clinical stages, they represent a tangible shift toward establishing chemically induced iPSC-derived treatments as a safe and effective pillar of global regenerative medicine.

About iRegene Therapeutics

Founded in 2017 by a team of international professionals, iRegene Therapeutics is a pioneer in applying “Chemical Induction” to precisely reprogram cell fate and optimize cellular functions for innovative cell therapies. Leveraging its proprietary “AI + Chemical Induction” platform, iRegene has built a robust pipeline targeting currently incurable diseases, including Parkinson’s disease and Multiple System Atrophy.

SHENZHEN, China, Feb. 23, 2026 /PRNewswire/ — Big Tree Cloud Holdings Limited (the “Company”) (NASDAQ: DSY) today announced that its AI business has made initial progress in technology development and services for enterprise clients (B2B), having signed its initial technical service agreements with a total contract value of approximately RMB 4.5 million (approximately US$620,000). This marks a key step in the Company’s strategic deployment in the AI commercial application sector.

Leveraging deep insights into industry needs and technological integration capabilities, the Company, through its operating entity, has partnered with multiple enterprise clients and signed technical service agreements. The agreements include providing comprehensive technology development for an AI-centric platform for a strategic partner, as well as for a third-party client in the education sector. These contracts encompass long-term framework collaborations, customized project development, and ongoing maintenance services. Such partnerships reflect market interest in the Company’s enterprise-focused platforms that integrate AI-powered functionalities. The Company provides enterprise-level platform development and system integration, including front-end and back-end development, architecture set up, system delivery, and other long-term, end-to-end services that effectively support businesses in achieving digital transformation and strategic implementation.

While these initial contracts are with enterprise clients (B2B), the platforms under development are designed to serve individual end-users (B2C). One of the platforms being developed is an AI learning and application platform intended to cultivate “AI application-oriented talent” for university students and young professionals. This strategy of empowering B2B clients who serve B2C users allows the Company to indirectly tap into the individual user market, laying a foundation for potential synergies between its enterprise services and the broader consumer technology ecosystem.

Management Commentary

Mr. Wenquan Zhu, Chairman of the Board of the Company, stated, “We will continue to invest in both enterprise and individual AI businesses, providing actionable solutions for enterprises through professional teams and building efficient learning systems for individual users to achieve sustainable growth.”

Ms. Xiaoxuan Zhu, Director and Co-Chief Executive Officer, added, “We are committed to building an AI platform that connects talent development with corporate needs. By developing platforms that bridge corporate needs with talent development and deepening the synergy between B2B and B2C segments, we aim to create long-term value for all stakeholders.”

About Big Tree Cloud

Founded in 2020, Big Tree Cloud is positioned as an international capital platform focused on industrial integration and strategic investment in China’s personal care industry. The Company is committed to empowering industries through capital operations. Currently, Big Tree Cloud is accelerating its expansion into the AI sector. This new business line aims to capture the growing market demand for AI skills, injecting fresh momentum into the Company’s development.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. federal securities laws. These statements involve risks and uncertainties and relate to, among other things, the Company’s future business development, growth strategies, and operational plans. These forward-looking statements include, but are not limited to, the Company’s ability to successfully develop and commercialize the AI platforms for its clients, the market acceptance of these platforms by end-users, the potential synergies between B2B and B2C businesses, and the Company’s ability to achieve sustainable growth. Actual results may differ materially from those expressed or implied in such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the evolving regulatory environment in China, competition in the AI industry, the Company’s ability to retain key personnel and technology, and other risks detailed in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements, except as required by law.

Investor Relations Contact
Ting Yan
Phone: +86 15986815865
Email: yanting@bigtreeclouds.com

LISHUI, China, Feb. 23, 2026 /PRNewswire/ — CN Energy Group. Inc. (NASDAQ: CNEY, “CNEY” or the “Company”) today announced that it has entered into a Share Purchase Agreement to acquire 100% of the outstanding shares of Blessing Logistics Ltd. (“Blessing Logistics”), an oil trading company incorporated in Alberta.

Under the terms of the agreement, the total purchase consideration is USD $2.0 million, expected to be satisfied through the issuance of Class A Ordinary Shares of CNEY. The number of shares to be issued will be determined based on the volume-weighted average price of CNEY’s Class A Ordinary Shares for the five consecutive trading days immediately preceding the closing date, subject to adjustment as provided in the agreement.

The closing of the transaction is subject to customary closing conditions and is expected to occur on or before March 31, 2026.

Founded in 2015, Blessing Logistics is a registered oil company with the Alberta Energy Regulator (AER) and holds Canadian crude oil export licenses. The company is also recognized as a qualified trader within the CNPC system, and is engaged primarily in oil trading as well as crude oil and asphalt exports.

The proposed acquisition is expected to provide CNEY with a fully operational North American entity and critical regulatory licenses supporting the Company’s strategic expansion into the North American oil market. The integration of Blessing Logistics is expected to strengthen CNEY’s operational capabilities and enhance its participation in global crude oil trading and export activities.

Mr. Wenhua Liu, interim CEO of CNEY, commented:

“We are pleased to enter into this agreement to acquire Blessing Logistics. This transaction represents an important step in executing CNEY’s global energy strategy. Following closing, we expect to leverage Blessing Logistics’ operational platform and licenses to expand our international crude oil trading business and create long-term value for our shareholders.”

About CN Energy Group. Inc.

CN Energy Group. Inc. is currently listed on NASDAQ under the symbol “CNEY.” CNEY has pioneered and specialized in producing high-quality recyclable activated carbon from raw carbon materials, converting harmful wastes into invaluable wealth and delivering significant financial, economic, environmental and ecologic benefits. CNEY’s products and services have been widely used by food and beverage producers, industrial and pharmaceutical manufacturers, as well as environmental protection enterprises. CNEY also develops and provides customizable robotics products, automation tools, and related software solutions for small and medium-sized industrial, logistics, and service businesses in North America. For more information, please visit the Company’s website at www.cneny.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements can generally be identified by words such as “anticipate,” “believe,” “expect,” “intend,” “may,” “plan,” “will,” “would,” and similar expressions. Forward-looking statements are based on current beliefs, expectations, and assumptions and are not guarantees of future performance.

These forward-looking statements include statements regarding the expected closing of the transaction, the expected benefits of the acquisition, and the Company’s strategic expansion plans. These statements are subject to risks and uncertainties, including those described under “Risk Factors” in the Company’s filings with the Securities and Exchange Commission, and actual results may differ materially, including if the parties do not enter into definitive agreements, required approvals are not obtained, or the Company is unable to integrate the business or realize the anticipated benefits of the transaction.

Forward-looking statements speak only as of the date hereof, and the Company undertakes no obligation to update them, except as required by law. Information on the Company’s website or social media is not incorporated by reference into this press release.